Reckitt Benckiser Group Plc (RB) Reveals 300 Million Pound Latin America Tie-In

Page 1 of 2

LONDON — Shares in Reckitt Benckiser Group Plc (LON:RB) lifted this morning following the group’s positive fourth-quarter and full-year earnings release, with management declaring that its strategy is “well on track.”

The earnings release also reported a three-year collaboration agreement with U.S. biopharmaceutical company Bristol Myers Squibb Co. (NYSE:BMY), for a number of market-leading over-the-counter consumer health-care brands in Latin America, including Brazil and Mexico.

The arrangement includes personnel, supply contracts, and an option to acquire legal title to the related intellectual property at the end of the collaboration period for a multiple of earnings.

Bristol Myers Squibb Co. (NYSE:BMY)Reckitt saw net revenue for Q4 hit 2.48 billion pounds, up 2% on actual exchange rates and 6% on constant rates. The full-year figure was 9.58 billion pounds, up 1% actual and 4% constant.

Like-for-like growth increased 7% in the fourth quarter, and 5% across the full year — well ahead of its market growth, driven by emerging-market areas and Europe/North America (ENA). Additionally, the company’s sales were boosted by “higher incidences of cold and flu.”

Health and hygiene led Reckitt’s growth, with a broad range of products, including Durex, Gaviscon, Strepsils, Dettol, Lysol, Harpic, and Finish. Chief Executive Officer Rakesh Kapoor commented, “We are laying the foundations for RB to succeed in a world where health and hygiene play an increasingly important role in terms of both economic and social development.”

Kapoor continued:

We enhanced our focus on our 16 power markets, many of which are in the emerging-market areas that now represent 44% of our core net revenue. I am very pleased that our 2012 achievements demonstrate the strength of this strategy and its ability to create sustainable value for all of our stakeholders.

While much has yet to be done and markets remain challenging, we approach 2013 with the confidence that we have the right strategic focus, the right organization and culture, and with the right innovation platforms. We are particularly excited by our entry into the vitamins, minerals, and supplements market with the acquisition of Schiff. We are supporting our brands with more and better-quality brand equity investment to deliver further growth in an increasingly competitive consumer environment.

We remain committed to our goal of net revenue growth on average +200bps per annum above our market growth, and moderate operating margin expansion (ex RBP). For 2013, we are targeting net revenue growth of +5-6% including acquisitions and disposals announced to date. Given the early achievement of cost savings in 2012, we expect to maintain operating margins in 2013. These targets exclude RBP.

Page 1 of 2

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!